Erschienen in:
27.04.2020 | ASO Author Reflections
ASO Author Reflections: Gene Signature Generated from Tumor Budding—A New Molecular Marker of Recurrence Risk
verfasst von:
Eiji Shinto, MD, Yuichiro Yoshida, PhD, Hideki Ueno, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 10/2020
Einloggen, um Zugang zu erhalten
Excerpt
Tumor budding has been defined as the presence of isolated single cells or small clusters of cells (up to 4 cells) in the stroma at the invasive tumor margin, which can be assessed in hematoxylin and eosin-stained sections.
1 Strong evidence indicates that tumor budding is an important and independent prognostic factor for patients with colon cancer.
2 In addition, global consensus on a standardized method for tumor budding assessment achieved at the International Tumor Budding Consensus Conference (ITBCC, 2016) will facilitate data integration and data sharing.
3 Budding foci are believed to originate because of molecular changes that induce cellular dissociation and/or active invasion into the surrounding stroma. However, despite the profound prognostic implications of the molecular phenomena that underlie tumor budding, these phenomena have not been elucidated to date. In addition, existing inter-observer variability regarding evaluation of tumor budding is a major limitation. …
